Suppr超能文献

尿激酶激活的人血浆中纤溶酶原和纤溶酶抑制剂复合物分子形式的鉴定

Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.

作者信息

Müllertz S, Thorsen S, Sottrup-Jensen L

出版信息

Biochem J. 1984 Oct 1;223(1):169-77. doi: 10.1042/bj2230169.

Abstract

Urokinase-activated human plasma was analysed by acetic acid/urea/polyacrylamide-gel electrophoresis. The bands representing plasminogen, the plasmin-alpha 2-plasmin inhibitor and plasmin-alpha 2-macroglobulin complexes were identified by immunoprecipitation with specific antibodies and by comparison with purified components. Plasminogen and the plasmin-inhibitor complexes were isolated from plasma or thrombin-clotted plasma containing 125I-labelled Glu-plasminogen (residues 1-790) and urokinase. The plasma was kept at 37 degrees C for 0.5 and 10 times the lysis time of the clotted plasma, the clotted plasma until lysis. The plasmin heavy chain from the plasmin-inhibitor complexes was subsequently prepared. Only in one case could a low-grade proteolytic conversion of Glu- forms into Lys/Met/Val-forms (residues 77-790, 68-790 and 78-790 respectively) during the preparations be detected. Sodium dodecyl sulphate/polyacrylamide-gel electrophoresis and N-terminal sequence analysis of the purified plasminogen and plasmin heavy chain showed the following. The plasminogen in plasma was on the Glu- form. Glu-plasmin constituted 0.74 and 0.58 of the plasmin bound to the alpha 2-plasmin inhibitor in plasma after brief and prolonged activation respectively. The rest was Lys/Met/Val-plasmin. The clotted plasma contained about equal amounts of Glu-plasminogen and Lys/Met/Val-plasminogen, and predominantly Lys/Met/Val-plasmin complexed to alpha 2-plasmin inhibitor and alpha 2-macroglobulin. The results of the analysis of the purified material substantiated the identity of radioactive protein bands in the gel after acetic acid/urea/polyacrylamide-gel electrophoresis.

摘要

采用乙酸/尿素/聚丙烯酰胺凝胶电泳法对尿激酶激活的人血浆进行分析。通过用特异性抗体进行免疫沉淀并与纯化成分进行比较,鉴定出代表纤溶酶原、纤溶酶-α2-纤溶酶抑制剂复合物和纤溶酶-α2-巨球蛋白复合物的条带。从含有125I标记的Glu-纤溶酶原(残基1-790)和尿激酶的血浆或凝血血浆中分离出纤溶酶原和纤溶酶-抑制剂复合物。将血浆在37℃下保存0.5倍和10倍于凝血血浆的溶解时间,直至凝血血浆溶解。随后制备纤溶酶-抑制剂复合物中的纤溶酶重链。在制备过程中,仅在一种情况下检测到Glu-形式向Lys/Met/Val-形式(分别为残基77-790、68-790和78-790)的低程度蛋白水解转化。纯化的纤溶酶原和纤溶酶重链的十二烷基硫酸钠/聚丙烯酰胺凝胶电泳和N端序列分析结果如下。血浆中的纤溶酶原呈Glu-形式。短暂激活和长时间激活后,血浆中与α2-纤溶酶抑制剂结合的纤溶酶中,Glu-纤溶酶分别占0.74和0.58。其余为Lys/Met/Val-纤溶酶。凝血血浆中Glu-纤溶酶原和Lys/Met/Val-纤溶酶原的含量大致相等,主要是与α2-纤溶酶抑制剂和α2-巨球蛋白复合的Lys/Met/Val-纤溶酶。乙酸/尿素/聚丙烯酰胺凝胶电泳后凝胶中放射性蛋白条带的纯化物质分析结果证实了其同一性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验